KIR and MHC Class I Immunogenetics in SIV Infection
KIR and MHC Class I Immunogenetics in SIV Infection
批准号:
10524739
负责人:
David T Evans
金额:
$65.01万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-11-14 至 2023-10-31
关键词:
Acquired Immunodeficiency SyndromeAddressAffectAllogenicAmino Acid SubstitutionAnimal ModelAnimalsAntibodiesB-LymphocytesBindingCD28 geneCD4 Positive T LymphocytesCell TherapyCellsCommunicable DiseasesContainmentCytoplasmic TailEpitopesExtracellular DomainFoundationsFundingGenesGenetic PolymorphismGenomeHIVHIV-1HLA-Bw4Histocompatibility Antigens Class IHumanImmune EvasionImmunizeImmunogeneticsImmunoglobulinsImmunologic Deficiency SyndromesImmunologicsInfectionKiller CellsKnowledgeLigand BindingLigandsLigationLightLymphoid TissueMHC Class I GenesMHC binding peptideMacacaMacaca mulattaMembraneModelingMutationNK Cell ActivationNK cell receptor NKB1Natural Killer CellsPeptidesPlasmaPlasmablastPopulationPredispositionPrimatesPropertyReagentReporterRoleSIVShapesSiteStainsT-Cell ReceptorViralViral AntigensViral Load resultViral PathogenesisVirusVirus DiseasesVirus Replicationadeno-associated viral vectorin vivoknowledge basenonhuman primatenovelpathogenic virusreceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Natural killer (NK) cells provide a critical early defense against viral pathogens by virtue of their ability to
recognize and kill virus-infected cells without prior antigenic stimulation. This is accomplished in part through
interactions between two highly polymorphic molecules; the killer-cell immunoglobulin-like receptors (KIRs) on
NK cells and their MHC class I ligands on target cells. KIR and HLA class I polymorphisms can have profound
effect on the course of HIV-1 infection and the efficacy of NK cell-based therapies for eradicating virus-infected
cells; however, animal studies to address underlying immunological mechanisms have been limited by our
understanding of KIR-MHC class I interactions in nonhuman primate models. Over the previous funding period,
we identified MHC class I ligands for five rhesus macaque KIRs and revealed a role for viral peptides in
suppressing NK cell activation as a potential mechanism of immune evasion. We also observed highly dynamic
changes in NK cell responses to SIV infection of KIR- and MHC class I-defined macaques, including an
enrichment of NK cells regulated by Bw4 ligands in lymphoid tissues that support high levels of virus
replication. Here we build on these studies to investigate specific hypotheses concerning the influence of viral
peptides on NK cell responses to virus-infected cells and the contribution of NK cells that recognize Bw4
ligands to the containment of immunodeficiency virus infection.
In Aim 1, we will define MHC class I ligands and isolate antibodies for the most common rhesus macaque
KIRs. This aim builds on recent studies to provide a broader knowledge base and key reagents for studying NK
cell responses in the rhesus macaque. In Aim 2, we will investigate the effects of viral peptides bound by MHC
class I ligands on NK cell recognition of virus-infected cells. We will determine the extent to which the
suppression of NK cell responses by viral peptides that stabilize MHC class I binding to inhibitory KIRs is a
common phenomenon or a unique property of certain KIR-MHC class I pairs, and whether peptides derived
from endogenously expressed viral antigens can also affect NK cell activity against virus-infected cells. In Aim
3, we will assess the contribution of a population of NK cells expressing a KIR specific for Bw4 ligands to the
containment of virus replication in animals by depleting these cells with a KIR-specific antibody prior to SIV
infection. These unprecedented studies will provide a better understanding of the functional effects of KIR-
MHC class I interactions on NK cell responses to immunodeficiency virus infection, including the role of viral
peptides in NK cell recognition of virus-infected cells and the impact of a dominant population of NK cells
regulated by Bw4 ligands on SIV pathogenesis.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pmed.1001900
发表时间:
2015-11
期刊:
PLoS medicine
影响因子:
15.8
作者:
[Hölzemer A, Thobakgale CF, Jimenez Cruz CA, Garcia-Beltran WF, Carlson JM, van Teijlingen NH, Mann JK, Jaggernath M, Kang SG, Körner C, Chung AW, Schafer JL, Evans DT, Alter G, Walker BD, Goulder PJ, Carrington M, Hartmann P, Pertel T, Zhou R, Ndung'u T, Altfeld M]
通讯作者:
Altfeld M
Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIVsmm/mac Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization.
HIV-1 V2 Apex 特异性抗体与 SIVsmm/mac 包膜糖蛋白的结合亲和力的差异将抗体依赖性细胞毒性与中和作用解耦。
DOI:
10.1128/mbio.01255-19
发表时间:
2019
期刊:
mBio
影响因子:
6.4
作者:
[vonBredow,Benjamin, Andrabi,Raiees, Grunst,Michael, Grandea3rd,AndresG, Le,Khoa, Song,Ge, Berndsen,ZacharyT, Porter,Katelyn, Pallesen,Jesper, Ward,AndrewB, Burton,DennisR, Evans,DavidT]
通讯作者:
Evans,DavidT
DOI:
10.4049/jimmunol.1400820
发表时间:
2014-09-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M Jr, Waterman D, Reeves RK, Masek-Hammerman K, Derdeyn CA, Alpert MD, Evans DT, Kohler H, Müller S, Robinson J, Lifson JD, Burton DR, Johnson RP, Haase AT]
通讯作者:
Haase AT
DOI:
10.4049/jimmunol.1302883
发表时间:
2014-02-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Schafer JL, Colantonio AD, Neidermyer WJ, Dudley DM, Connole M, O'Connor DH, Evans DT]
通讯作者:
Evans DT
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model
-
批准号:10403162
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2021
-
负责人:David T Evans
-
依托单位:
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model
-
批准号:10591883
-
项目类别:
-
资助金额:$45.09万
-
财政年份:2021
-
负责人:David T Evans
-
依托单位:
Tethering lentiviral restriction to Fc-mediated antibody responses
-
批准号:10425358
-
项目类别:
-
资助金额:$70.77万
-
财政年份:2020
-
负责人:David T Evans
-
依托单位:
Tethering lentiviral restriction to Fc-mediated antibody responses
-
批准号:10082732
-
项目类别:
-
资助金额:$45.44万
-
财政年份:2020
-
负责人:David T Evans
-
依托单位:
Tethering lentiviral restriction to Fc-mediated antibody responses
-
批准号:10203816
-
项目类别:
-
资助金额:$45.58万
-
财政年份:2020
-
负责人:David T Evans
-
依托单位:
Tethering lentiviral restriction to Fc-mediated antibody responses
-
批准号:10661036
-
项目类别:
-
资助金额:$77.6万
-
财政年份:2020
-
负责人:David T Evans
-
依托单位:
Assessing ADCC and Fc-mediated Protection against HIV
-
批准号:10671615
-
项目类别:
-
资助金额:$76.71万
-
财政年份:2019
-
负责人:David T Evans
-
依托单位:
Assessing ADCC and Fc-mediated Protection against HIV
-
批准号:10808458
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2019
-
负责人:David T Evans
-
依托单位:
Assessing ADCC and Fc-mediated Protection against HIV
-
批准号:10226317
-
项目类别:
-
资助金额:$76.5万
-
财政年份:2019
-
负责人:David T Evans
-
依托单位:
Assessing ADCC and Fc-mediated Protection against HIV
-
批准号:10458659
-
项目类别:
-
资助金额:$76.76万
-
财政年份:2019
-
负责人:David T Evans
-
依托单位:
Fcgamma receptor-mediated suppression of immunodeficiency virus replication
-
批准号:9275920
-
项目类别:
-
资助金额:$76.52万
-
财政年份:2015
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8790734
-
项目类别:
-
资助金额:$43.24万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8415838
-
项目类别:
-
资助金额:$14.36万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8604135
-
项目类别:
-
资助金额:$51.02万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8326887
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8894969
-
项目类别:
-
资助金额:$3.39万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
Lentiviral Resistance to Tetherin
-
批准号:8717000
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2012
-
负责人:David T Evans
-
依托单位:
A NOVEL ASSAY FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
-
批准号:8357976
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2011
-
负责人:David T Evans
-
依托单位:
KIR and MHC Class I Immunogenetics in SIV Infection
-
批准号:10054150
-
项目类别:
-
资助金额:$70.42万
-
财政年份:2011
-
负责人:David T Evans
-
依托单位:
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH
-
批准号:8357938
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2011
-
负责人:David T Evans
-
依托单位:
海外基金